Oncology RCM, built around the chemo chair
Buy-and-bill drug billing, JW/JZ waste automation, and regimen-level prior authorization for oncology practices.
Why oncology billing is different
Oncology billing revolves around the treatment chair. Drug acquisition cost, payer reimbursement, and clinical documentation all have to line up before a single chemotherapy claim goes out. Generic billing software treats a J-code like any other line item, missing the waste modifiers, regimen tracking, and biosimilar substitution rules that protect an oncology practice's drug margin.
What generic software misses
- Drug waste going unbilled because JW and JZ modifiers are calculated by hand, if at all.
- Authorizations approved for one regimen that no longer match after a dose change or added agent.
- Biosimilar substitutions left on the original reference-product code, mismatched to what was actually administered.
- 340B and non-340B inventory tracked in the same ledger, with no separation for covered-entity claims.
What the platform does about it
Regimen-matched prior authorization
Authorizations are held against the full regimen, not a single visit, so mismatches surface before infusion day.
JW/JZ waste automation
Documented dose is compared against vial size automatically, with the correct waste modifier applied at charge entry.
Drug margin reporting
Acquisition cost, contracted reimbursement, and actual payment are compared by drug, regimen, and payer.
Denial routing by reason and payer
High-value chemotherapy denials are grouped and routed to the right queue, with timely-filing deadlines surfaced first.
Generic software vs. Unlimited Financials
Get the full oncology brochure
Sent to your work email, usually the same day.
SEE IT LIVE
See your own J-codes, not a sample chart
Bring your regimens and payer mix to a demo, and we'll show you exactly how the platform handles them.
★★★★★5/5
★★★★★5/5
6,500+ specialty providers